AMM reveals Doctors' Choice Awards finalists

Share this article:
AMM reveals Doctors' Choice Awards finalists
AMM reveals Doctors' Choice Awards finalists

In what could be seen as a positive sign of the times, the Association of Medical Media (AMM) announced the finalists for its 2010 Doctors' Choice Awards, which recognizes the best pharmaceutical journal ads, as chosen by physicians. The AMM established the awards in 2003, but did not give the awards last year, due to budgetary concerns.

This year, however, the awards are on, with one winner selected in each of the 14 therapeutic specialties and six physician assistant/nurse practitioner categories, plus one overall winner. The format for the awards this year has been changed from a luncheon to a networking-friendly cocktail reception, to be held on September 16 at Comix Comedy Club in New York City.

The three finalists for the overall highest scoring ads, according to an AMM release, are ads for Roche/Genentech's Avastin, created by Harrison and Star; Forest Laboratories' Lexapro, created by ghg (Grey Healthcare Group); and Roche/Genentech/Biogen Idec's Rituxan, created by AbelsonTaylor. For a listing of the finalists in each of the therapeutic specialties, see the AMM's release.

Advertisements were judged on their “ability to communicate clearly and quickly, help with clinical decisions, prompt seeking more information or re-examining treatment, generate interest, add to information provided by company sales representatives and underscore the value of the product prescribed,” according to the release. The study was conducted by Readex Research, and drew more than 4,600 responses from doctors, their assistants, and nurse practitioners. The 325 ads that were judged represent the 86 most widely-advertised products in 2009, according to the release. 

The Doctors' Choice Awards reception will be emceed by Vince Parry, founder and leader of Y Brand, inVentiv Health's branding group. Parry has conducted branding initiatives for some of the biggest pharmaceutical companies, including Johnson & Johnson, Merck, Allergan, Lilly and Roche, according to the AMM's website.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...